TL;DR Stage 4 pancreatic cancer treatment primarily involves systemic chemotherapy, with FOLFIRINOX achieving median survival of 11 months and gemcitabine/nab-paclitaxel regimens reaching 8.5 months [3] Only 49.1% of stage 4 pancreatic cancer patients receive systemic therapy, with significant disparities based on age, insurance status, and comorbidity scores [4] Targeted therapies including PARP inhibitors for BRCA mutations, NTRK inhibitors, and KRAS inhibitors provide pers

TL;DR FOLFIRINOX chemotherapy extends median overall survival to 11 months in metastatic pancreatic cancer, compared to 8.5 months with gemcitabine plus nab-paclitaxel-based regimens [1] Only 49.1% of stage IV pancreatic cancer patients receive systemic therapy, with significant disparities based on age, insurance status, and treatment facility type [2] Dr.Bh arat Patodiya's multidisciplinary approach integrates medical oncology, surgical consultation, and personalized treat